Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

von Hippel-Lindau Disease 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lung Neoplasms 1Kidney Neoplasms 1Hodgkin Disease 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Medullary 1Breast Neoplasms 1Adenocarcinoma, Follicular 1

Interventions

Carboplatin 106Pemetrexed 74Paclitaxel 58Cisplatin 52Erlotinib Hydrochloride 51Radiotherapy 49Docetaxel 43Gemcitabine 41Bevacizumab 41pembrolizumab 30Nivolumab 25Radiosurgery 21Etoposide 20durvalumab 13Cetuximab 13Specimen Handling 12Ipilimumab 12Magnetic Resonance Spectroscopy 11Gefitinib 11Vinorelbine 10Taxes 10Radiation 10Albumin-Bound Paclitaxel 10osimertinib 9Biopsy 9vandetanib 8Topotecan 7Platinum 7Irinotecan 7Drug Therapy 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lung Neoplasms × tanespimycin × Clear all
NCT01228435 2017-12-04

IPI-504 in NSCLC Patients With ALK Translocations

Massachusetts General Hospital

Phase 2 Terminated
3 enrolled 5 charts
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡